An observational study in Exanthema, Dengue Fever and Chikungunya, sponsored by Hospital Israelita Albert Einstein. Not yet recruiting. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2025-08-08.
Sponsored by Hospital Israelita Albert Einstein · Observational
Exanthematous fevers are a global public health problem. The spread of arboviruses due to various factors, including climate change, has resulted in major epidemics such as the one that occurred in Brazil in 2024, representing an extremely concerning scenario from both epidemiological and healthcare perspectives. In addition to this, the reemergence of childhood exanthematous diseases in several countries, including Brazil, is alarming and occurs due to declining vaccination coverage and increased migratory movements. These diseases present overlapping clinical symptoms, and their differential diagnosis is often challenging, which, in a context of dengue and Chikungunya epidemics like the current one, may lead to underreporting of diseases such as measles and rubella. This project aims to build a prospective registry of the occurrence of dengue, Chikungunya, measles, and rubella in various healthcare centers in Brazil, in order to better understand the epidemiological scenario, identify clinical variables associated with different diagnoses, and describe healthcare bottlenecks that may hinder proper reporting and identification of these diseases.
68 studies on the registry are indexed under Exanthema; 11 are open to participants now.
This study's planned enrollment of 830 is above the median of 71 across 18 observational studies indexed under Exanthema.
Browse Exanthema studies →Hospital Israelita Albert Einstein is the lead sponsor of 147 studies on the registry; 32 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Participants without symptoms suspicious for the diseases presented.
Individuals with confirmed cases of the aforementioned infections prior to recruitment.
Individuals who, even presenting the symptoms described in the inclusion criteria, did not have samples collected for viral panel testing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Individuals from newborns (zero years old) to 18 years of age, of both sexes.
Suspected individuals with the following criteria:
Measles: Presenting fever and rash associated with cough and/or runny nose and/or conjunctivitis, regardless of age or vaccination status;
Rubella: Presenting fever, rash, and lymphadenopathy, regardless of age or vaccination status;
Dengue and Chikungunya: Presenting myalgia, arthralgia, headache, retro-orbital pain, nausea, vomiting, rash, petechiae, positive tourniquet test, or leukopenia and/or lymph node enlargement;
Individuals who, meeting the above criteria, underwent sample collection for viral panel testing for the differential diagnosis of exanthematous diseases."
Exclusion Criteria:
-
Prevalence of positive infections for one or more infectious diseases (rubella, measles, dengue, and Chikungunya)
Prevalence of positive infections for one or more infectious diseases (rubella, measles, dengue, and Chikungunya)
Time frame: From enrollment to the end of follow-up (30 days).
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Israelita Albert Einstein →